
Alberto Bocchetta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8426696/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Exemplar scoring identifies genetically separable phenotypes of lithium responsive bipolar disorder. Translational Psychiatry, 2021, 11, 36.	2.4	16
2	Microcytic Anaemia as Susceptibility Factors in Bipolar Spectrum Disorders: Review of the Literature, Replication Survey, and Co-Segregation within Families. Clinical Practice and Epidemiology in Mental Health, 2021, 17, 81-91.	0.6	0
3	Prediction of lithium response using clinical data. Acta Psychiatrica Scandinavica, 2020, 141, 131-141.	2.2	50
4	Telomere attrition and inflammatory load in severe psychiatric disorders and in response to psychotropic medications. Neuropsychopharmacology, 2020, 45, 2229-2238.	2.8	21
5	Differences in telomere length between patients with bipolar disorder and controls are influenced by lithium treatment. Pharmacogenomics, 2020, 21, 533-540.	0.6	26
6	Thyroid and renal tumors in patients treated with long-term lithium: case series from a lithium clinic, review of the literature and international pharmacovigilance reports. International Journal of Bipolar Disorders, 2018, 6, 17.	0.8	8
7	Internet use by older adults with bipolar disorder: international survey results. International Journal of Bipolar Disorders, 2018, 6, 20.	0.8	13
8	Circulating antithyroid antibodies contribute to the decrease of glomerular filtration rate in lithium-treated patients: a longitudinal study. International Journal of Bipolar Disorders, 2018, 6, 3.	0.8	13
9	Psychotropic Medication of Acute Episodes of Mood Disorders: Current Prescription Attitude in Two Psychiatric Wards in Cagliari, Italy. Clinical Practice and Epidemiology in Mental Health, 2018, 14, 236-249.	0.6	2
10	Interstitial lung disease induced by fluoxetine: Systematic review of literature and analysis of Vigiaccess, Eudravigilance and a national pharmacovigilance database. Pharmacological Research, 2017, 120, 294-301.	3.1	12
11	An observational study of 110 elderly lithium-treated patients followed up for 6Âyears with particular reference to renal function. International Journal of Bipolar Disorders, 2017, 5, 19.	0.8	17
12	Pharmacogenetics of lithium effects on glomerular function in bipolar disorder patients under chronic lithium treatment: a pilot study. Neuroscience Letters, 2017, 638, 1-4.	1.0	13
13	International multi-site survey on the use of online support groups in bipolar disorder. Nordic Journal of Psychiatry, 2017, 71, 473-476.	0.7	4
14	Long-term lithium treatment in bipolar disorder: effects on glomerular filtration rate and other metabolic parameters. International Journal of Bipolar Disorders, 2017, 5, 27.	0.8	81
15	The Sardinian Puzzle: Concentration of Major Psychoses and Suicide in the Same Sub-Regions Across One Century. Clinical Practice and Epidemiology in Mental Health, 2017, 13, 246-254.	0.6	9
16	Online information seeking by patients with bipolar disorder: results from an international multisite survey. International Journal of Bipolar Disorders, 2016, 4, 17.	0.8	35
17	Internet use by patients with bipolar disorder: Results from an international multisite survey. Psychiatry Research, 2016, 242, 388-394.	1.7	36
18	Bipolar disorder and antithyroid antibodies: review and case series. International Journal of Bipolar Disorders, 2016, 4, 5,	0.8	27

Alberto Bocchetta

#	Article	IF	CITATIONS
19	Long-term lithium and estimated glomerular filtration rate. Lancet Psychiatry,the, 2016, 3, 105-106.	3.7	2
20	Renal function during long-term lithium treatment: a cross-sectional and longitudinal study. BMC Medicine, 2015, 13, 12.	2.3	55
21	Continuation Versus Discontinuation of Lithium During Pregnancy. Journal of Clinical Psychopharmacology, 2014, 34, 407-410.	0.7	10
22	Duration of lithium treatment is a risk factor for reduced glomerular function: a cross-sectional study. BMC Medicine, 2013, 11, 33.	2.3	54
23	Ammonemia in Bipolar Patients on Maintenance Treatment With Valproic Acid. Journal of Clinical Psychopharmacology, 2012, 32, 148-150.	0.7	4
24	The Use of Antidepressant Drugs and the Lifetime Prevalence of Major Depressive Disorders in Italy. Clinical Practice and Epidemiology in Mental Health, 2010, 1, 94-100.	0.6	0
25	Affective psychosis, Hashimoto's thyroiditis, and brain perfusion abnormalities: case report. Clinical Practice and Epidemiology in Mental Health, 2007, 3, 31.	0.6	20
26	Long-Term Lithium Treatment and Survival From External Causes Including Suicide. Journal of Clinical Psychopharmacology, 2007, 27, 544-546.	0.7	9
27	Fifteen-year follow-up of thyroid function in lithium patients. Journal of Endocrinological Investigation, 2007, 30, 363-366.	1.8	65
28	Lithium treatment and thyroid abnormalities. Clinical Practice and Epidemiology in Mental Health, 2006, 2, 23.	0.6	95
29	Mortality Follow-up of Patients Since Commencing Lithium Therapy. Journal of Clinical Psychopharmacology, 2005, 25, 197-199.	0.7	7
30	Heterozygous beta-thalassaemia as a susceptibility factor in mood disorders: excessive prevalence in bipolar patients. Clinical Practice and Epidemiology in Mental Health, 2005, 1, 6.	0.6	9
31	Psychotic mania in glucose-6-phosphate-dehydrogenase-deficient subjects. , 2003, 2, 6.		25
32	Ten-Year Follow-up of Thyroid Function in Lithium Patients. Journal of Clinical Psychopharmacology, 2001, 21, 594-598.	0.7	46
33	Association of personal and familial suicide risk with low serum cholesterol concentration in male lithium patients. Acta Psychiatrica Scandinavica, 2001, 104, 37-41.	2.2	34
34	Family-based association study between bipolar disorder andDRD2, DRD4, DAT, andSERT in Sardinia. , 1999, 88, 522-526.		41
35	Maternal inheritance of manic depression in hemizygotes for the G6PD-Mediterranean mutation. Indirect evidence for Xq28 transmission in Sardinia. Psychiatric Genetics, 1999, 9, 63-68.	0.6	13
36	Association between dopamine receptor genes and migraine without aura in a Sardinian sample. Neurology, 1998, 51, 781-786.	1.5	114

Alberto Bocchetta

#	Article	IF	CITATIONS
37	Suicidal Behavior On and Off Lithium Prophylaxis in a Group of Patients With Prior Suicide Attempts. Journal of Clinical Psychopharmacology, 1998, 18, 384-389.	0.7	46
38	Value of Thyroid Echography in the Long-Term Follow-Up of Lithium-Treated Patients. Neuropsychobiology, 1997, 36, 37-41.	0.9	19
39	No evidence of association between dopamine D3 receptor gene and bipolar affective disorder. , 1997, 74, 137-139.		20
40	Carbamazepine Augmentation in Lithium-Refractory Bipolar Patients. Journal of Clinical Psychopharmacology, 1997, 17, 92-96.	0.7	24
41	Heterogeneity of monoaminergic vesicular carriers: Pharmacological evidence using MPP+ as a marker. Life Sciences, 1996, 59, 1703-1710.	2.0	1
42	Sixâ€year followâ€up of thyroid function during lithium treatment. Acta Psychiatrica Scandinavica, 1996, 94, 45-48.	2.2	31
43	Thyroid function during carbamazepine. Biological Psychiatry, 1994, 36, 135-136.	0.7	5
44	Is bipolar disorder linked to Xq28?. Nature Genetics, 1994, 6, 224-224.	9.4	20
45	The course of thyroid abnormalities during lithium treatment: a two-year follow-up study. Acta Psychiatrica Scandinavica, 1992, 86, 38-41.	2.2	47
46	Thyroid abnormalities during lithium treatment. Acta Psychiatrica Scandinavica, 1991, 83, 193-198.	2.2	85
47	Bipolar affective disorder and heterozygous beta-thalassemia. American Journal of Psychiatry, 1990, 147, 1094b-1094.	4.0	10
48	Familial rates of affective illness in Sardinia with special reference to schizoaffective disorder. European Archives of Psychiatry and Clinical Neuroscience, 1990, 240, 16-20.	1.8	4
49	Glucose-6-phosphate dehydrogenase deficiency and psychoses. , 1990, , 211-220.		1
50	Covalent protein binding of a metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to mouse and monkey brain in vitro and in vivo. Biochemical Pharmacology, 1988, 37, 4163-4169.	2.0	4
51	PARKINSON'S DISEASE AND PESTICIDES. Lancet, The, 1986, 328, 1163.	6.3	54
52	A reactive metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is formed in rat brain in vitro by type B monoamine oxidase. Journal of Pharmacology and Experimental Therapeutics, 1986, 238, 648-52.	1.3	7
53	1 -Methyl-4-Phenyl- 1,2,3,6-Tetrahydropyridine: Correspondence of Its Binding Sites to Monoamine Oxidase in Rat Brain, and Inhibition of Dopamine Oxidative Deamination In Vivo and In Vitro. Journal of Neurochemistry, 1985, 45, 673-676.	2.1	32
54	AETIOLOGY OF PARKINSON'S DISEASE. Lancet, The, 1985, 325, 112-113.	6.3	1

#	Article	IF	CITATIONS
55	Proteolytic degradation of neuronal benzodiazepine binding sites. Life Sciences, 1984, 34, 293-299.	2.0	22
56	Inhibition of [3H] MPTP binding to rat brain by pargyline Biochemical Pharmacology, 1984, 33, 4105-4107.	2.0	13
57	Linkage between Xâ€chromosome markers and manicâ€depressive illness. Acta Psychiatrica Scandinavica, 1984, 70, 282-287.	2.2	72